Lesson
Ear Anatomy and Symptom Triage
The canal, tympanic membrane, middle ear, inner ear, auditory nerve, mastoid, jaw, teeth, and throat can all generate an ear complaint. Localization protects time-sensitive hearing and neurologic pathways.
- External and middle ear
- Sudden hearing loss
- Vertigo
- Referred pain
- Red flags
External inflammation, trauma, foreign body, or wax
Effusion, perforation, tube, or acute infection
Sudden loss, vertigo, or ototoxic exposure
Escalate focal or time-sensitive findings
Localize before treating
Tragal tenderness and canal edema support external disease. Membrane findings, pressure, or effusion suggest middle-ear disease. Sudden hearing change, vertigo, or tinnitus can reflect inner-ear or neural disease, while jaw, dental, throat, or neck disease can refer pain.
Protect sudden hearing loss
Sudden sensorineural hearing loss is time sensitive. A patient reporting abrupt unilateral hearing loss, often with tinnitus or vertigo, needs urgent audiologic and otolaryngology evaluation rather than a prolonged trial of cerumen treatment.
Act within hearing-recovery windows
For adults with suspected sudden sensorineural loss, arrange audiometry immediately when available and within fourteen days of onset; this outer limit is not permission to wait. A clinician may offer initial corticosteroids within two weeks. Incomplete recovery warrants an offer of intratympanic steroid salvage at two to six weeks. Hyperbaric oxygen with steroids is an option within two weeks initially or within one month as salvage. Evaluate retrocochlear disease with MRI or auditory brainstem response. Avoid routine head CT, blanket laboratory panels, and routine antivirals or vasoactive treatments. Repeat audiometry after treatment and within six months.
Recognize invasive and neurologic danger
Severe persistent pain, mastoid swelling or tenderness, pinna displacement, cranial nerve deficit, systemic toxicity, trauma, foreign body, bleeding, severe headache, or high-risk immune status requires urgent evaluation matched to severity.
Use hearing as a functional vital sign
Clarify baseline, communication impact, device use, one versus both ears, fluctuation, and progression. A clear canal does not end the evaluation when hearing remains abnormal.
Quick check
Checking for saved practice…
Lesson
Acute Otitis Externa
Diffuse acute otitis externa is a painful canal infection commonly linked to moisture or trauma. Uncomplicated disease is treated topically, while pain and obstructed delivery are addressed directly.
- Tragal tenderness
- Topical therapy
- Analgesia
- Canal wick
- Reassessment
Separate canal disease from middle and referred pain
Use trained cleaning or a wick when delivery is blocked
Reserve systemic antibiotics for spread or defined host risk
Question diagnosis, delivery, fungus, dermatitis, and extension
Recognize canal infection
Rapid onset of ear pain, tragal or pinna tenderness, canal edema, erythema, and discharge supports diffuse acute otitis externa. Water exposure, cotton swabs, scratching, earbuds, hearing devices, dermatitis, and narrow canals can disrupt the protective barrier.
Use topical therapy first
AAO-HNS guidance recommends topical preparations as initial therapy for uncomplicated diffuse disease. Routine systemic antibiotics are reserved for extension beyond the canal or defined host and delivery factors. Choice depends on membrane status, allergy, formulation, organism, cost, and adherence.
Treat pain and blocked delivery
Assess pain severity and use suitable systemic analgesia. When edema or debris prevents drops from reaching the canal, trained aural toilet or wick placement can restore contact. Increasing drop volume alone does not solve a physical obstruction.
Tailor water, device and travel advice
Keep water out of the infected canal during treatment. Limit in-canal hearing aids and earphones until pain and drainage have stopped, while arranging communication support if needed. Flying advice requires assessment of symptoms, congestion and middle-ear pressure equalization. CDC notes that travelers with ear, nose or sinus infection or severe congestion may postpone flying to avoid barotrauma. Do not turn this into either automatic flight clearance or an unexplained universal ban.
Reassess early nonresponse
Failure to improve within 48 to 72 hours prompts review of diagnosis, adherence, technique, canal patency, fungal disease, dermatitis, foreign body, perforation, resistant organism, and invasive extension.
Quick check
Checking for saved practice…
Lesson
Tympanic-Membrane and Host Risk
A perforation or tube exposes the middle ear, while diabetes and immune compromise increase invasive infection risk. Product and urgency must reflect both barrier and host.
- Perforation
- Tympanostomy tube
- Ototoxicity
- Diabetes
- Malignant otitis externa
Tube, perforation, surgery, or uncertainty changes exposure
Look for severe persistent pain and invasive extension
Treat cranial findings as urgent
Protect inner-ear structures when the barrier is open
Treat the membrane as a barrier decision
A tube, known perforation, trauma, surgery, or uncertain membrane changes which tissues contact the drug. Do not treat inability to see the membrane as proof that it is intact.
Avoid avoidable ototoxic exposure
When middle-ear exposure is possible, select a non-ototoxic preparation appropriate for that route. Aminoglycoside-containing products can create cochlear or vestibular risk when they cross a perforation unless specialist direction establishes a specific plan.
Recognize invasive external disease
Severe nocturnal pain, granulation, persistent discharge, cranial neuropathy, poor response, and diabetes or immune compromise raise concern for necrotizing external otitis and skull-base osteomyelitis. This is not routine swimmer's ear.
Escalate by host and depth
Assess glycemic control, immune status, prior radiation or surgery, hearing, balance, cranial nerves, fever, extension, and response. Urgent specialist evaluation and systemic management are required when invasive disease is suspected.
Quick check
Checking for saved practice…
Lesson
Otic Pharmacotherapy
Otic products differ by antimicrobial, anti-inflammatory component, vehicle, suspension behavior, sterility, pH, age, diagnosis, and membrane exposure. Exact labeling controls use.
- Fluoroquinolones
- Combination drops
- Ototoxic ingredients
- Suspensions
- Product specificity
Use high canal exposure for uncomplicated disease
Account for tube or perforation when present
Do not assume an unseen membrane is intact
Respect suspension and temperature instructions
Use fluoroquinolones deliberately
Otic fluoroquinolone products provide local antibacterial activity, and selected formulations are suitable with tympanostomy tubes or perforation. Diagnosis and label still matter because not every product has the same indication, dose, vehicle, or age range.
Separate antimicrobial and anti-inflammatory roles
Combination ciprofloxacin and dexamethasone treats selected bacterial otic infections while dexamethasone reduces inflammation. Current labeling requires otic-only use, suspension shaking, exact dosing, and excludes viral and fungal canal infection.
Do not interchange eye and ear products blindly
Some ophthalmic solutions can be used in the ear under clinician direction, but otic products must never be placed in the eye. Sterility, isotonicity, pH, concentration, vehicle, and labeling differ. The route printed on the container must be verified.
Distinguish ciprofloxacin-dexamethasone delivery
Ciprofloxacin 0.3% with dexamethasone 0.1% otic suspension treats acute otitis externa and pediatric tube-associated acute otitis media from six months of age. Use four drops twice daily for seven days. Shake, hand-warm for one to two minutes, and keep the treated ear upward for one minute. For tube-associated middle-ear infection, pump the tragus five times. Store the reviewed generic at 20-25°C without freezing, protect from light, and discard after therapy. Persistent drainage after treatment or at least two episodes within six months requires further evaluation.
Select ofloxacin by indication
Ofloxacin 0.3% otic solution has separate regimens: external infection uses five drops daily from six months through age twelve, or ten drops daily from age thirteen, for seven days. Tube-associated acute middle-ear infection at ages one through twelve uses five drops twice daily for ten days. Chronic suppurative middle-ear infection with perforation at age twelve or older uses ten drops twice daily for fourteen days. Confirm diagnosis and prescribed dose when patient-leaflet age wording is unclear. Hand-warm for one to two minutes, keep the ear upward for five minutes, and use four gentle tragal pumps for middle-ear treatment. Avoid use with quinolone hypersensitivity; stop for allergic reactions. Store at 25°C, with permitted excursions of 15-30°C, protected from light.
Apply Cortisporin TC formulation limits
Cortisporin TC combines colistin, neomycin, hydrocortisone and the dispersing agent thonzonium. Shake; adults use five drops three or four times daily, with four drops suggested for pediatric patients. Keep the treated ear upward for five minutes. Use below age one is unestablished. Store at 20-25°C. Limit treatment to ten days: neomycin can permanently damage hearing. Stop for irritation or sensitization. Its label cautions about perforation; the otitis externa guideline instead directs selecting non-ototoxic therapy when the membrane is open or suspected open. Do not use this combination as the routine perforation option.
Keep Cipro HC separate from tube-safe products
Cipro HC contains ciprofloxacin 0.2% and hydrocortisone 1% in a preserved, nonsterile suspension. It treats susceptible acute otitis externa from age one year. Do not use it with a known or suspected eardrum perforation. Quinolone or hydrocortisone hypersensitivity and viral canal infection are contraindications; the reviewed dropper cap contains natural rubber latex. This product is not for the eye or injection.
Deliver the Cipro HC course precisely
Shake before dosing and hand-warm for one to two minutes. Instill three drops in the affected ear twice daily for seven days, keeping that ear upward for 30-60 seconds. Protect from light and discard the remainder after treatment. Stop and seek advice for rash or an allergic reaction. Persistent infection at one week calls for culture-guided reassessment; earlier worsening still needs review.
Prepare the formulation correctly
Shake suspensions immediately before use. Warm the closed bottle in the hands for one to two minutes when the label directs to reduce dizziness from cold drops. Do not microwave, use hot water, contaminate the tip, or continue beyond the prescribed course.
Quick check
Checking for saved practice…
Lesson
Ear-Drop Administration
Preparation, age-appropriate canal straightening, dropper-tip clearance, distribution, and dwell time determine whether a topical product reaches the affected tissue.
- Hand warming
- Pinna direction
- Tip clearance
- Tragal pumping
- Dwell time
Reduce cold-triggered dizziness without uncontrolled heat
Use age-appropriate pinna movement
Avoid contamination and give the exact dose
Use gentle tragal movement when directed
Prepare before positioning
Wash hands, verify patient, product, route, affected ear, dose, expiration, seal, formulation, and storage. Shake and hand-warm only as directed. A written laterality plan prevents right and left errors.
Write the route and side in full
AD, AS and AU traditionally indicate right ear, left ear and both ears; OD, OS and OU indicate right eye, left eye and both eyes. These abbreviations can be confused with one another. Write the intended site in full, confirm unclear orders, and match the label to the patient demonstration. A familiar bottle or drug name does not establish the route.
Straighten the canal by age
Position the affected ear upward. General teaching uses up-and-back movement for adults and older children and down-and-back for young children, but confirm the product-specific instructions. The reviewed ciprofloxacin/dexamethasone and ofloxacin labels describe up-and-back movement for external-canal infection and distinct tragal-pumping steps for middle-ear treatment. Do not insert the dropper into the canal.
Instill and distribute
Place the exact number of drops without touching the tip. Gentle tragal pumping can help distribute solution when directed. A wick may need to be saturated according to clinician instruction. Avoid forceful pressure or instrumentation.
Maintain contact and protect the bottle
Remain with the treated ear upward for the label-directed interval. Recap without wiping the tip on a nonsterile surface. Complete the course, avoid sharing, and use return demonstration when dexterity or caregiver administration is uncertain.
Quick check
Checking for saved practice…
Lesson
Cerumen Impaction
Cerumen is protective. It becomes impaction when symptoms occur or needed examination is blocked. Removal method depends on the membrane, anatomy, host risk, devices, and prior surgery.
- Clinical impaction
- Cerumenolytics
- Irrigation
- Manual removal
- Unsafe cleaning
Hearing, fullness, pain, tinnitus, or blocked view
Tube, surgery, stenosis, bleeding, diabetes, or immunity
Cerumenolytic, irrigation, or manual care by risk
Find the next diagnosis after wax clears
Treat clinical impaction, not visible wax
Symptoms can include hearing loss, fullness, pain, itch, tinnitus, or cough, and wax can prevent examination. Asymptomatic nonobstructive cerumen usually does not need removal because it protects and lubricates the canal.
Identify modifying factors first
Perforation, tube, ear surgery, canal stenosis, exostoses, dermatologic disease, anticoagulation, diabetes, immune compromise, hearing devices, and inability to report symptoms can change whether cerumenolytics, irrigation, manual removal, or referral is safest.
Check who cannot report a wax problem
Obstructing wax in a young child or a person with cognitive impairment deserves prompt assessment even without a symptom report. Inspect hearing-aid users for wax during healthcare encounters. After office removal, document whether impaction has resolved; persistent impaction after initial treatment warrants referral to a clinician with suitable equipment and training. Prior canal surgery, radiation, recurrent external infection or substantial canal skin disease needs individualized care beyond the routine guideline population.
Use short evidence-based removal
Water, saline, mineral oil, hydrogen peroxide, carbamide peroxide, irrigation, and manual techniques may be used in selected patients. No one cerumenolytic is best for everyone. Follow the exact label and stop for pain, bleeding, discharge, dizziness, or hearing change.
Apply the Debrox four-day limit
Debrox carbamide peroxide 6.5% uses five to ten drops twice daily for up to four days, unless a clinician directs otherwise. Keep the ear tilted for several minutes and the applicator outside the canal. Manufacturer guidance includes ages twelve and older; children younger than twelve need a doctor. Follow the dispensed package and obtain advice when its wording or the clinical situation is unclear. Seek advice before use with pain, drainage, rash, dizziness, eardrum injury or recent surgery. Stop and obtain assessment if wax persists or more than four days are needed. Store upright in its carton at no more than 25°C. Bubbling or crackling can accompany oxygen release.
Reject unsafe canal cleaning
Cotton swabs push wax deeper and can injure the canal or membrane. Ear candles can burn and do not provide reliable benefit. Probing, pressurized devices, and blind removal are unsafe. Persistent symptoms after clearance need another diagnosis.
Quick check
Checking for saved practice…
Lesson
Tinnitus Assessment and Care
Tinnitus is a symptom, not one disease. Pulsatility, laterality, sudden hearing change, duration, burden, and associated neurologic or otologic findings determine evaluation and management.
- Primary tinnitus
- Pulsatile tinnitus
- Asymmetric hearing
- Medication exposure
- CBT and hearing care
Protect sudden hearing-loss pathways
Investigate vascular, neural, or structural sources
Measure distress, mood, concentration, and safety
Reduce impact without promising a universal cure
Classify the sound and context
Document pulse synchrony, one or both ears, sudden or gradual onset, duration, constancy, hearing loss, vertigo, trauma, noise, medicines, sleep, mood, and function. Objective or pulsatile sound and asymmetric or focal findings require targeted evaluation.
Protect secondary pathways
Sudden hearing loss, focal neurologic symptoms, severe vertigo, trauma, unilateral persistent tinnitus, pulsatile tinnitus, asymmetric hearing, or concerning headache and visual symptoms can require urgent audiology, otolaryngology, vascular, or neurologic assessment.
Match referral speed to the finding
Hearing loss that develops over three days or less within the past thirty days, with tinnitus, warrants referral to be seen within twenty-four hours. Sudden loss beginning more than thirty days ago or hearing that worsens over four to ninety days warrants assessment within two weeks under NICE guidance. Neurologic deficits, stroke symptoms or acute uncontrolled vertigo need emergency care. Pulsatile tinnitus needs targeted assessment; associated acute neurologic or other red flags determine emergency urgency. Suicidal thoughts require immediate safety assessment and connection to crisis or emergency care. Stable chronic symptoms without these findings follow a planned hearing and symptom evaluation.
Use imaging selectively
Routine imaging is not recommended for bilateral nonpulsatile tinnitus with symmetric hearing loss and an otherwise normal history and examination. Pulsatile sound, one-sided findings, asymmetric hearing or focal neurologic signs require a different evaluation. Imaging should answer a clinical question raised by that assessment.
Audit exposures without oversimplifying
Salicylates and other medicines can cause or worsen tinnitus in dose and host context. Review timing, kidney function, concentrations when relevant, interactions, noise, and alternatives. Do not stop an essential drug abruptly without a safe plan.
Measure benefit and preserve treatment indications
Use a validated questionnaire such as the Tinnitus Functional Index to follow daily-life impact. The 2024 VA/DoD recommendations supporting CBT, sound-based care and hearing aids for hearing loss are conditional. Antidepressants, anticonvulsants, supplements and intratympanic steroids are not recommended as tinnitus treatments; a separate condition can still justify its own indicated therapy.
Treat burden rather than promising a cure
For persistent bothersome primary tinnitus, education, hearing evaluation, cognitive behavioral therapy, hearing aids when indicated, and selected sound strategies can improve function. Routine drug and supplement cures are not supported. Screen sleep, depression, anxiety, and suicidality.
Quick check
Checking for saved practice…
Lesson
Special Populations and Follow-Up
Children, older adults, people with diabetes or immune compromise, hearing-device users, and patients with altered ear anatomy need individualized technique, monitoring, and referral.
- Children
- Older adults
- Hearing devices
- High-risk hosts
- Closed-loop care
Treat neonatal and poorly examinable disease differently
Balance indication, evidence, and drainage reduction
Define a response window for every plan
Escalate whenever the pattern threatens vision
Use exact pediatric assessment and labeling
Do not stop after wax if impairment remains
Reassess acute otitis externa if not improving in 48 to 72 hours
Act on mastoid, neurologic, invasive, or sudden findings
Use age-specific pediatric care
A child with a foreign body, tube, fever, severe pain, mastoid finding, discharge, hearing or speech concern, trauma, or unreliable examination needs direct assessment. Verify exact pediatric labeling and caregiver return technique rather than scaling adult instructions.
Connect hearing to older-adult safety
Cerumen, hearing devices, canal skin, polypharmacy, tinnitus, cognition, falls, and age-related loss can coexist. Remove reversible obstruction, but obtain audiologic evaluation when hearing remains impaired because communication and cognition are clinical outcomes.
Lower the threshold in high-risk hosts
Diabetes, immune compromise, prior radiation, ear surgery, altered canal anatomy, anticoagulation, or recurrent severe disease changes the safety of home treatment and the urgency of persistent pain, discharge, granulation, or cranial findings.
Close the treatment loop
Arrange reassessment if treated acute otitis externa is not improving within 48 to 72 hours and a defined short course for cerumenolytics. Escalate worsening pain, fever, swelling, mastoid change, discharge, sudden hearing loss, vertigo, neurologic signs, bleeding, or failure to improve.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 46 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- NICE NG155. Tinnitus referral recommendations 1.2.1-1.2.7
- ISMP Canada. Dangerous abbreviations update, 2025
- AAO-HNS. Choosing Wisely tinnitus imaging recommendation
- DailyMed. Ofloxacin otic prescribing and patient information
- CDC Yellow Book. Air travel and barotrauma
- AAO-HNS. Acute otitis externa patient summary
- AAO-HNS. Cerumen impaction guideline abstract and key actions, 2017
- VA/DoD. Tinnitus provider summary, 2024
- AAO-HNS. Sudden Hearing Loss guideline key actions, 2019
- DailyMed. Cortisporin TC, July 2024
- Debrox manufacturer directions and FAQs
- DailyMed. Cipro HC prescribing information, August 2025
- DailyMed. Debrox Drug Facts, January 2025
- AAO-HNS Acute Otitis Externa Guideline
- AAO-HNS Cerumen Impaction Guideline
- AAO-HNS Tinnitus Guideline
- AAO-HNS Clinical Practice Guideline Directory
- DailyMed Ciprofloxacin and Dexamethasone Otic Label